

## **BLU-667 (Pralsetinib)**

ALTERNATE NAME: cis-N-{(1S)-1-[6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl]ethyl}-1-methoxy-4-{4-methyl-6-[(5-methyl-1H-

pyrazol-3-yl)amino]pyrimidin-2-yl}cyclohexane-1-carboxamide

Pralsetinib free base

1 mg

5 mg

BLU667 BLU 667

**CATALOG #:** B2548-1 B2548-5

STRUCTURE:

2000g

MOLECULAR WEIGHT: 533.6

**CAS NUMBER:** 2097132-94-8

APPEARANCE: Crystalline solid

PURITY: ≥98% by HPLC

**SOLUBILITY**: >50 mg/ml DMSO

**DESCRIPTION:** BLU-667 (Pralsetinib) is a highly potent and selective, next generation RET inhibitor with IC<sub>50</sub> of 0.3-0.4

nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. In vivo, BLU-667 potently inhibits growth of NSCLC and thyroid cancer xenografts driven by various RET mutations and

fusions without inhibiting VEGFR2.

**STORAGE TEMPERATURE:** -20°C. Protect from light

**HANDLING:** Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

**RELATED PRODUCTS:** 

Carbozantinib (1935) SU-5416 (9491) BBT-594 (B2114) Lenvatinib (B1157) Regorafenib (2891)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.